Table 3 |
||||||
|
Anti-MCV, anti-CCP, and IgM-RF at baseline and after 6 and 12 months of infliximab therapy |
||||||
|
Response 6 months |
Baseline |
6 months |
Response 12 months |
Baseline |
12 months |
|
|
|
||||||
|
Anti-MCV, U/mL |
Responders (n = 11) |
654 (89–2,918) |
535 (56–3,000) |
Responders (n = 15) |
293 (61–2,918) |
117a (48–3,582) |
|
Nonresponders (n = 12) |
307 (60–1,145) |
227 (40–1,234) |
Nonresponders (n = 8) |
363 (60–1,145) |
227 (47–1,500) |
|
|
Anti-CCP, U/mL |
Responders (n = 11) |
1,402 (83–11,360) |
1,300 (54–11,370) |
Responders (n = 15) |
1,246 (83–11,360) |
837b (48–12,640) |
|
Nonresponders (n = 12) |
962 (130–4,232) |
1,134 (74–2,392) |
Nonresponders (n = 8) |
1,169 (275–4,232) |
1,331 (126–4,313) |
|
|
IgM-RF, IU/mL |
Responders (n = 11) |
91.5 (10–424) |
58 (10–216) |
Responders (n = 15) |
74.5 (9–781) |
49.5c (10–214) |
|
Nonresponders (n = 12) |
205 (9–949) |
133c (10–367) |
Nonresponders (n = 8) |
283 (14–949) |
152c (35–463) |
|
|
|
||||||
|
Values are expressed as median (range), and the nonparametric Wilcoxon signed rank test was used for paired comparisons of changes in anti-CCP and anti-MCV titres between responders and nonresponders. aP < 0.01 versus baseline; bP < 0.05 versus baseline; cP = 0.02 versus baseline. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor. |
||||||
|
Nicaise Roland et al. Arthritis Research & Therapy 2008 10:R142 doi:10.1186/ar2570 |
||||||
